Six wellness peptides win backing from FDA advisory committeenews2026-07-27T17:21:05+00:00July 27th, 2026|Endpoints News|
Yarrow to begin trading as it targets Graves; FDA approves Otsuka’s ADHD pillnews2026-07-27T15:40:29+00:00July 27th, 2026|Endpoints News|
MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 winnews2026-07-27T15:17:42+00:00July 27th, 2026|Endpoints News|
Legend CEO Ying Huang resigns; Carvykti chief named interim leadernews2026-07-27T13:38:43+00:00July 27th, 2026|Endpoints News|
Sarepta turns to Michael Severino as CEO, looking to move past recent turmoilnews2026-07-27T12:30:43+00:00July 27th, 2026|Endpoints News|
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filingsnews2026-07-27T11:08:17+00:00July 27th, 2026|Endpoints News|
AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare diseasenews2026-07-27T11:03:08+00:00July 27th, 2026|Endpoints News|
Schrödinger debuts AI agent Bunsen to use its physics softwarenews2026-07-27T11:00:49+00:00July 27th, 2026|Endpoints News|
Argenx to pick up autoimmune biotech Forte Biosciences for $2.2Bnews2026-07-27T10:46:03+00:00July 27th, 2026|Endpoints News|
Anthropic’s life science plans; Novartis CEO on China deals; and more news2026-07-25T10:00:11+00:00July 25th, 2026|Endpoints News|